Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elafibranor crossover study in adults with non-alcoholic fatty liver
NL-OMON47978Phase 2Active, not recruiting
- Sponsor
- Genfit
- Start
- Aug 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of elafibranor in metabolic dysfunction-associated steatotic liver disease (MASLD) (2 arms), sponsored by Genfit. Primary endpoint: Relative amount of saturated fatty acids in the liver. Started Aug 2019; status: active, not recruiting.
02
Drugs
elafibranor
03
Conditions
metabolic dysfunction-associated steatotic liver disease (MASLD)
Beyond the preview
Go deeper on NL-OMON47978.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47978.